Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 4/20 | 0.73 |
| ▸ | GSK3B | P49841 | 4/20 | 0.73 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | WNT3A | P56704 | 2/20 | 0.58 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.57 |
| ▸ | EP300 | Q09472 | 8/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21285856 | 1.00 | WNT1 (0.73) | WNT1GSK3BDYRK1AMEN1KMT2A | |
| SCHEMBL29324438 | 0.90 | GSK3B (0.60) | WNT1GSK3BDYRK1AMAPK8EP300 | |
| SCHEMBL22953923 | 0.88 | EP300 (0.62) | WNT1GSK3BDYRK1AMEN1KMT2A | |
| SCHEMBL29313603 | 0.86 | WNT1 (0.57) | WNT1GSK3BDYRK1AEP300MAPK1 | |
| SCHEMBL22953924 | 0.85 | MAPK8 (0.62) | WNT1GSK3BDYRK1AWNT3AMAPK8 | |
| SCHEMBL21426361 | 0.85 | AURKB (0.74) | WNT1GSK3BDYRK1AEP300MAPK1 | |
| SCHEMBL19517223 | 0.85 | WNT1 (1.00) | WNT1GSK3BDYRK1AMAPK8 | |
| SCHEMBL21286084 | 0.84 | WNT1 (0.64) | WNT1GSK3BDYRK1AMEN1KMT2A | |
| SCHEMBL21285730 | 0.84 | EP300 (0.56) | WNT1GSK3BDYRK1AMAPK8EP300 | |
| SCHEMBL20951562 | 0.84 | WNT1 (0.76) | WNT1GSK3BDYRK1AMAPK8MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20220331304-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| CN-114450005-A | Compounds for the treatment of neurological disorders | 星座制药公司 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331304-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CLN6, ACHE, NLN | WNT1 4453/4885GSK3B 1954/4885DYRK1A 3730/4885 |
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | WNT1 1899/4885GSK3B 1775/4885DYRK1A 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.